Subsequent neoplasms in the fifth and sixth decades of life in the Childhood Cancer Survivor Study cohort.

Authors

null

Lucie Marie Turcotte

University of Minnesota, Minneapolis, MN

Lucie Marie Turcotte , John Whitton , Debra L. Friedman , Sue Hammond , Gregory T. Armstrong , Wendy M. Leisenring , Leslie L. Robison , Joseph Philip Neglia

Organizations

University of Minnesota, Minneapolis, MN, Fred Hutchinson Cancer Research Center, Seattle, WA, Vanderbilt-Ingram Cancer Center, Nashville, TN, Nationwide Children's Hospital, Columbus, OH, St. Jude Children's Research Hospital, Memphis, TN, Fred Hutchinson Cancer Research Center, Seattle Children's Hospital, Seattle, WA

Research Funding

No funding sources reported

Background: The risk of subsequent neoplasms (SN) in childhood cancer survivors increases over time, but only limited data exist on risk beyond 40 years of age. Methods: Occurrence of SN was evaluated in 3171 5-year adult survivors of childhood cancer ≥40 years of age (median 44 years, range 40-58) following cancer diagnosed <21 years of age, between 1970-1986. Cumulative incidence and standardized incidence ratio (SIR), with corresponding 95% confidence intervals (CI) were used to evaluate risk of SN and subsequent invasive malignant neoplasm (SMN), respectively. SIR were calculated using age-, sex- and calendar year-specific incidence from the NCI Surveillance, Epidemiology and End Results program. Survivors with a history of SN prior to age 40 (SNpos) were also compared to those without previous SN (SNneg). Results: A total of 371 SN were diagnosed ≥40 years of age, including 136 SMN (SIR=2.2, CI 1.9-2.5), 191 non-melanoma skin cancers (NMSC), and 44 meningiomas and other non-invasive neoplasms. Cumulative incidence of a new SN after age 40 was 34.6% (CI 28.7-40.6) at age 55, with SNpos having a higher incidence compared to SNneg 57.6% (CI 46.7-68.6) versus 30.4% (CI 23.8-37). While cumulative incidence of new SMN at age 55 was similar for SNneg and SNpos (15.4% (CI 10.2-20.5) vs. 20.8% (CI 12.5-29.1)), SNpos experienced more NMSC compared to SNneg (cumulative incidence 16.2% (CI 10.8-21.6) vs. 38.2% (CI 27.9-48.5)). Compared to the U.S. population, risk of a SMN was elevated for both SNneg and SNpos (SIR=2.0, CI 1.7-2.4 vs. SIR=3.0, CI 2.2-4.0). Breast cancer was the most common SMN beyond age 40, and also carried the largest risk (SIR=5.5, CI 4.5-6.7). Significantly elevated risks were also seen for renal cancer (SIR=3.9, CI 2.0-7.5), soft tissue sarcoma (SIR=2.6, CI 1.5-4.4) and thyroid carcinoma (SIR=1.9, CI 1.0-3.5). Hodgkin lymphoma (SIR=3.6, CI 3.0-4.4) and radiation therapy (SIR=2.6, CI 2.2-3.1) were associated with high risk of SMN although the magnitude of risk for SNneg and SNposdid not differ substantially. Conclusions: Risk of SN remains significantly elevated after age 40. These data have important implications for screening and should inform anticipatory guidance provided to childhood cancer survivors.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Pediatric Oncology

Track

Pediatric Oncology

Sub Track

Survivorship

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 10039)

DOI

10.1200/jco.2014.32.15_suppl.10039

Abstract #

10039

Poster Bd #

340

Abstract Disclosures

Similar Abstracts